US survey highlights gene patent pitfalls
This article was originally published in Clinica
Executive Summary
A US team believes it has uncovered the first evidence to support growing concern that the commercialisation of molecular genetic discoveries could place limitations on clinical practice. In a commentary published in Nature (February 7), the researchers report that US laboratories have discontinued clinical genetic-testing services for haemochromatosis because of the cost of the patent.